Form 4: Ocular Therapeutix CSO Granted Significant Equity Awards

Ocular Therapeutix's Chief Scientific Officer, Jeffrey S. Heier, received grants of restricted stock units and stock options, alongside an employee stock purchase plan acquisition.

Summary

• Jeffrey S. Heier, Chief Scientific Officer, was granted 79,112 restricted stock units (RSUs) on January 2, 2026, under the 2021 Stock Incentive Plan.
• Each RSU represents a right to receive one share of common stock, vesting over three years (1/3 on the one-year anniversary, then 1/3 annually).
• He also acquired 1,373 shares of common stock on December 31, 2025, through the Amended and Restated 2014 Employee Stock Purchase Plan.
• Additionally, Heier was granted stock options for 240,932 shares on January 2, 2026, with an exercise price of $11.82 per share and an expiration date of January 1, 2036.
• These stock options vest over four years, with 1/48 vesting monthly starting one month after the grant date.
• Following these transactions, Heier beneficially owns 326,425 shares of common stock and 240,932 stock options.

Sentiment

Score: 7

Explanation: The filing indicates positive alignment of executive incentives with company performance through significant equity grants, which is generally viewed favorably by investors as it promotes long-term commitment and shareholder value creation. No negative events or dispositions were reported.

Positives

• Significant equity grants (79,112 RSUs and 240,932 stock options) to a key executive, aligning management interests with shareholder value.
• Acquisition of 1,373 shares through an Employee Stock Purchase Plan, indicating continued commitment.
• The grants are subject to continued service, incentivizing long-term retention of a Chief Scientific Officer.

Future Outlook

The grants of restricted stock units and stock options are subject to multi-year vesting schedules, indicating a long-term incentive structure tied to the reporting person's continued service to the Corporation. The RSUs will vest over three years, and the stock options will vest over four years.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology or pharmaceutical industry, where equity grants are commonly used to attract, retain, and incentivize key scientific and executive talent. Such grants align the interests of the Chief Scientific Officer with the long-term performance and innovation goals of Ocular Therapeutix, a company focused on ophthalmic therapies.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and stock options with multi-year vesting schedules, are a common practice in the biotech and pharmaceutical sectors.
• Companies like Regeneron Pharmaceuticals, Biogen, and Amgen frequently utilize similar structures to incentivize their scientific and executive leadership.
• The specific number of units and options granted to a Chief Scientific Officer would typically be benchmarked against peer companies of similar market capitalization, stage of development, and R&D pipeline, though specific comparable figures are not provided in this filing.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance.
• Employees: The ESPP indicates a broader employee benefit program, potentially boosting morale and retention.

Next Steps

• Vesting of 79,112 Restricted Stock Units over three years, with 1/3 vesting on the one-year anniversary of January 2, 2026, and subsequent 1/3 portions vesting annually thereafter.
• Vesting of 240,932 stock options over four years, with 1/48 vesting monthly beginning on the one-month anniversary of January 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive, which is a standard practice for incentivizing management. While the grants align executive interests with long-term company performance, this specific filing does not provide new fundamental information about the company's operational or financial performance that would warrant a change in investment recommendation. It reinforces a 'hold' stance, awaiting more comprehensive financial or strategic updates.

Keywords

Ocular Therapeutix, OCUL, Jeffrey S. Heier, Chief Scientific Officer, Restricted Stock Units, Stock Options, Employee Stock Purchase Plan, Equity Grant, Insider Transaction, Form 4, Executive Compensation